Answers are grounded in this paper and cite their sources.
Reports efficacy and safety of frexalimab in participants with relapsing multiple sclerosis, suggesting long-term benefits.
To report efficacy and safety of frexalimab at Week (W)144 (3 years) in the phase 2 (NCT04879628) open-label extension (OLE) in participants with relapsing multiple sclerosis (pwRMS).
No takes yet. Share an insight, caveat, or question.
Vermersch et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: